Literature DB >> 9929497

Molecular and physical mechanisms of first-pass extraction.

S D Hall1, K E Thummel, P B Watkins, K S Lown, L Z Benet, M F Paine, R R Mayo, D K Turgeon, D G Bailey, R J Fontana, S A Wrighton.   

Abstract

This is a report of a symposium held at the March 1997 meeting of the American Society for Pharmacology and Therapeutics in San Diego. Our understanding of the events that control first-pass drug elimination in humans has increased tremendously by two sequential discoveries. First, cytochrome P-450s 3A4 and 5 are expressed at high concentrations in both hepatocytes and upper intestinal enterocytes, and therefore limit the systemic availability of many drugs. Second, P-glycoprotein is expressed at the lumenal surface of the intestinal epithelium and therefore also acts to oppose the absorption of unchanged drug. The following discussion brings together our current understandings of these interrelated phenomena to aid a more complete picture of how they may contribute both qualitatively and quantitatively to first-pass elimination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9929497

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  40 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.

Authors:  Lawrence M DuBuske
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

5.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

6.  Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Authors:  R E Polk; D F Brophy; D S Israel; R Patron; B M Sadler; G E Chittick; W T Symonds; Y Lou; D Kristoff; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

7.  Molecular cloning and expression analysis of cytochrome P450 3A gene in the turbot Scophthalmus maximus.

Authors:  Airong Sun; Jian Li; Jingzhou Huang; Zhiqiang Chang; Jitao Li; Qi Wang
Journal:  Fish Physiol Biochem       Date:  2013-03-23       Impact factor: 2.794

8.  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro.

Authors:  Bryan A Ward; Alan Morocho; Abdullah Kandil; Raymond E Galinsky; David A Flockhart; Zeruesenay Desta
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

9.  An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.

Authors:  Paul A Keown; Bryce Kiberd; Robert Balshaw; Shideh Khorasheh; Carlo Marra; Philip Belitsky; Zoltan Kalo
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice.

Authors:  Vibeke Andersen; Natalie Pedersen; Niels-Erik Larsen; Jesper Sonne; Steen Larsen
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.